Drugs / QD202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07581210 | Oct 2025 → Aug 2026 overdue | ischemic stroke | Shanghai QuietD Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QD202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07581210 ↗ |
| Modality | Peptide | “QD202 is a 19 amino acid peptide” NCT07581210 ↗ |
| Route | Intravenous | “60 minute intravenous infusion” NCT07581210 ↗ |